Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: Clin Microbiol Infect. 2022 Aug 10;29(1):77–84. doi: 10.1016/j.cmi.2022.07.026

Fig. 2.

Fig. 2.

Proportion of countries with the availability of antituberculosis drugs in the absence of drug susceptibility testing for those drugs; numbers of countries with available data for amikacin (AM) = 35, moxifloxacin (MFX) = 39, levofloxacin (LFX) = 40, bedaquiline (BDQ) = 35; ethionamide/prothionamide (ETO/PTO) = 32, clofazimine (CFZ) = 32, linezolid (LZD) = 40, delamanid (DLM) = 24, cycloserine/terizidone (CS/TRD) = 39, para-aminosalicylic acid (PAS) = 28, imipenem (IMP) = 23, and meropenem (MPM) = 27. WHO group A medicines are displayed in dark blue, group B medicines in medium blue, and group C medicines in light blue.